ASX Health shares: PromarkerD canagliflozin compared to blood protein canagliflozin is effective
Proteomic blood test to see if canagliflozin is working
A Proteomics study (ASX: PIQ) found that the drug canagliflozin reduced Promarker D risk predictors for diabetic nephropathy.
PromarkerD is a newly developed blood test that can predict kidney disease in diabetics before clinical symptoms appear. This will help doctors make treatment decisions and improve outcomes for patients with type 2 diabetes.
A recent study conducted in collaboration with Janssen Research and Development looked at PromarkerD outcomes in patients treated with canagliflozin.
It involved 2,000 participants and found that taking the drug PromarkerD significantly reduced the risk of developing kidney disease compared to a placebo.
According to PromarkerD, this effect was strongest in participants at high risk for baseline renal failure.
Proteomics CEO Richard Lipscomb said the results show the benefit of using the PromarkerD test, which can identify patients with diabetes who have no symptoms of kidney disease but are still at high risk for the disease.
Canagliflozin also seems to reduce the risk of diabetic kidney disease.
“This is a great example of early intervention and the use of precision medicine to slow or stop the onset of the disease,” Lipscomb said.
The study was published as an editorial in the peer-reviewed Journal of Clinical Medicine.
Artria has filed an application with the US FDA
Medical technology company Artrya (ASX: AYA) today announced that it has made significant progress in seeking US FDA regulatory approval for its product Salix Coronary Anatomy (SCA) ) mine.
The company has now announced that it has submitted a Q-Submission (Q-Sub) to the FDA and expects to meet with the regulator within 9-12 weeks.
The Q-Sub conference is an important part of the FDA process, in which Artrya will present her approach to software development and clinical reader study design for FDA approval for the method. its product development.
“This feedback can significantly save time and money in the FDA approval process,” said Artira CEO Matthew Regan.
“Since Artria redefined FDA’s regulatory strategy in the first quarter, the team has worked hard to get us there.”
Salix Coronary Anatomy is a web-based software designed for use by trained healthcare professionals as an interactive tool for viewing and analyzing computed tomography (CT) data.
This tool is used to quantify the presence and extent of coronary artery plaque (e.g., atherosclerosis) and stenosis, and to quantify calcifications (calcium evaluation) in patients undergoing angiography. coronary computed tomography (CCTA) to evaluate coronary artery disease.
The company expects to file a final 510(k) filing with the FDA by the end of October, in line with previous market filings.
UBI launches blood glucose monitoring feature for pets
Universal Biosensors (ASX: UBI) has launched the PETRACKR blood glucose meter for dogs and cats with diabetes.
At the same time as the launch, UBI announced that it has signed three distribution partnerships in the US and Canada and has received initial orders of approximately 280,000 USD.
10,000 PETRACKR analyzers and 375,000 diabetes test strips were shipped or shipped to UBI warehouses in the US and Europe.
UBI is expected to announce the first round of sales to additional distributors over the next 6-8 weeks, with some stores in the US, Europe and Asia Pacific already in the works. negotiation and final documentation.
The company said revenue from the three contracts is expected to exceed $2 million in the first year, with revenue growth expected in subsequent years.
Glucose monitoring in diabetic animals (dogs and cats) is a growing market worth $270 million annually.
Glucose test strip production is about $150 million per year and device production is about $1 million per year.
John Sharman, CEO of UBI said: “The market is growing at a rate of 12% annually, mainly due to increasing pet adoption and rising rates of pet obesity globally. world”.
